APYX Apyx Medical Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 719135 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY24.4%
TTM net income YoY42.0%
TTM EPS YoY—
Revenue 3-yr CAGR5.8%
Net income 3-yr CAGR—
Margins
Gross margin63.4%
Operating margin-5.5%
Net margin-14.2%
FCF margin-14.9%
EBITDA margin-4.1%
Returns
ROE-109.0%
ROA-14.2%
ROIC (approx.)-14.9%
Asset turnover1.00x
Leverage & solvency
Liabilities / assets83.7%
Debt / equity3.69x
Current ratio4.95x
Interest coverage-0.59x
Cash quality & payout
Operating cash flow / net income0.98x
Accruals ratio-0.4%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $52.84M | $48.10M |
| Cost of revenue | $19.80M | $18.74M |
| Gross profit | $33.04M | $29.36M |
| R&D expense | $3.37M | $5.08M |
| SG&A expense | $15.80M | $18.86M |
| Operating income | -$6.45M | -$18.84M |
| Interest expense | $5.59M | $5.91M |
| Pretax income | -$10.84M | -$23.31M |
| Income tax | $270,000 | $252,000 |
| Net income | -$11.21M | -$23.46M |
| EBITDA | -$5.79M | -$18.25M |
| EPS (basic) | -0.27 | -0.66 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $31.74M | $31.74M |
| Receivables | $16.78M | $15.48M |
| Inventory | $8.60M | $7.56M |
| Current assets | $58.47M | $56.44M |
| PP&E, net | $2.37M | $1.99M |
| Total assets | $66.84M | $64.84M |
| Current liabilities | $11.70M | $10.72M |
| Long-term debt | $34.85M | $33.89M |
| Total debt | $34.85M | $33.89M |
| Total liabilities | $52.01M | $50.51M |
| Shareholders' equity | $14.54M | $14.21M |
| Net debt | $3.11M | $2.15M |
| Shares outstanding | 41.79M | 37.79M |
| Cash flow statement | ||
| Operating cash flow | -$8.00M | -$18.05M |
| Capital expenditure | $1.11M | $722,000 |
| Free cash flow | -$9.12M | -$18.77M |
| Investing cash flow | -$1.11M | -$722,000 |
| Financing cash flow | $9.58M | $6.75M |
| Depreciation & amortization | $655,000 | $599,000 |
| Stock-based compensation | $2.00M | $4.01M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.